Vietnam is continuing to strengthen its infectious disease surveillance and diagnostic capabilities, driving robust demand for molecular testing technologies across hospitals, public health laboratories and clinical diagnostics providers.
Industry analysis estimates the country's molecular infectious disease testing market is currently valued at US$45–60 million in 2025 and is projected to reach US$80–110 million by 2030. Infectious disease testing remains the largest application within Vietnam's broader molecular diagnostics market, reflecting the country's ongoing investment in laboratory modernisation and disease surveillance.
According to IMARC Group, Vietnam's overall molecular diagnostics market reached approximately US$108.9 million in 2024 and is forecast to grow to US$195.4 million by 2033, at a CAGR of 6.71%. The report highlights increasing adoption of PCR-based diagnostics, advances in genomics and greater investment in precision medicine as key drivers of market growth. (imarcgroup.com)
Several factors are accelerating adoption of molecular infectious disease testing in Vietnam:
- Continued investment in national infectious disease surveillance programmes.
- Rising incidence of tuberculosis, dengue fever, hepatitis, HIV and seasonal respiratory infections.
- Expansion of hospital molecular diagnostic laboratories.
- Growing adoption of real-time PCR, multiplex PCR and syndromic testing panels.
- Increased investment in antimicrobial resistance (AMR) monitoring and genomic surveillance.
- Strengthening laboratory preparedness following the COVID-19 pandemic. (marketsandmarkets.com)
Globally, molecular diagnostics is becoming an increasingly important component of modern healthcare. According to MarketsandMarkets, the global molecular diagnostics market is projected to grow from US$20.4 billion in 2024 to US$31.8 billion by 2029 driven by increasing demand for rapid, highly accurate diagnostic testing and advances in automation and molecular technologies. Infectious disease testing continues to represent the largest application segment within the market. (marketsandmarkets.com)
Modern molecular testing platforms are transforming disease detection by enabling clinicians to identify pathogens more rapidly and accurately than conventional laboratory methods. Technologies including real-time PCR, automated sample preparation, multiplex molecular panels and next-generation sequencing are supporting earlier diagnosis, improved patient outcomes and more effective public health responses.
Leading suppliers such as Roche Diagnostics, Abbott, Thermo Fisher Scientific, Danaher (Cepheid), bioMérieux, QIAGEN, Seegene, Hologic and Bio-Rad Laboratories continue to expand their molecular diagnostics portfolios to meet growing global demand.
As Vietnam continues to modernise its healthcare system and strengthen preparedness for both endemic and emerging infectious diseases, molecular infectious disease testing is expected to remain one of the fastest-growing segments of the country's diagnostics market. For providers of molecular diagnostics, laboratory technologies, automation and genomic surveillance solutions, Vietnam represents a significant and expanding opportunity within Southeast Asia.
READ THE FULL INSIGHTS REPORT